| Neuromyelitis Optica
Enspryng vs Ultomiris
Side-by-side clinical, coverage, and cost comparison for neuromyelitis optica.Deep comparison between: Enspryng vs Ultomiris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUltomiris has a higher rate of injection site reactions vs Enspryng based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ultomiris but not Enspryng, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Enspryng
Ultomiris
At A Glance
SC injection
Every 4 weeks
IL-6 receptor antagonist
IV infusion
Every 4-8 weeks
C5 complement inhibitor
Indications
- Neuromyelitis Optica
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
Dosing
Neuromyelitis Optica Loading dose of 120 mg SC at Weeks 0, 2, and 4; maintenance dose of 120 mg every 4 weeks.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome (5 to <40 kg) Weight-based IV loading dose (600-1,200 mg), followed by weight-based maintenance dose every 4 weeks (5 to <20 kg) or every 8 weeks (20 to <40 kg), starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (>=40 kg) Weight-based IV loading dose (2,400-3,000 mg), followed by weight-based maintenance dose (3,000-3,600 mg) every 8 weeks, starting 2 weeks after loading dose.
Contraindications
- Known hypersensitivity to satralizumab or any inactive ingredient
- Active Hepatitis B infection
- Active or untreated latent tuberculosis
- Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=15%) nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, nausea
Serious infections, elevated liver enzymes, decreased neutrophil counts, hypersensitivity reactions
Most common (>=10%) Upper respiratory tract infection, headache, diarrhea, nausea, vomiting, hypertension, pyrexia, back pain, arthralgia, COVID-19
Serious Meningococcal infections, other infections (including fatal COVID-19 pneumonia and sepsis), infusion-related reactions
Postmarketing Anaphylaxis, cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin
Pharmacology
IL-6 receptor antagonist; recombinant humanized anti-human IL-6 receptor monoclonal antibody that inhibits IL-6-mediated signaling by binding to soluble and membrane-bound IL-6 receptors.
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds complement protein C5 with high affinity, preventing its cleavage to C5a (proinflammatory anaphylatoxin) and C5b (initiating subunit of the membrane attack complex), thereby inhibiting MAC formation and terminal complement-mediated tissue damage in PNH, aHUS, gMG, and NMOSD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Enspryng
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (3/12) · Qty limit (9/12)
Ultomiris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Enspryng
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Ultomiris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Enspryng
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Ultomiris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Neuromyelitis Optica Spectrum Disorder (NMOSD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Ultomiris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EnspryngView full Enspryng profile
UltomirisView full Ultomiris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.